Fund moves
0.2%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
COLL · NASDAQ · Pharmaceuticals
Collegium Pharmaceutical, Inc. (COLL) · oqro.io/stocks/COLL · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$24.72−0.49 (−1.94%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Collegium Pharmaceutical, Inc. was filed in the last 90 days. The latest on record was on May 12, 2017.
Since 2015, Collegium Pharmaceutical, Inc. insiders reported 11 open-market purchases and 187 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2017.
No open-market sale by an insider of Collegium Pharmaceutical, Inc. (COLL) was filed with the SEC in the last 90 days.
No trade in Collegium Pharmaceutical, Inc. (COLL) was disclosed by a member of Congress in the last 12 months.
Collegium Pharmaceutical, Inc.'s next results are expected on Feb 24, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−43.8% (−$19.23) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $43.95 on Nov 20, 2025 to $24.72 on Nov 20, 2026 (−43.8%). Disclosed in this range: 5 insider trades, 6 pre-arranged insider sales, 0 Congress trades, and 7 13F position changes for 3 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceuticals company based in Stoughton, Massachusetts.
Last 12 months
−43.8%
Market value
$768M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5.19M shares sold short (16.7% of shares outstanding), −3.4% vs the previous count, 9.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$781M
+23.6% vs the year before
Net income, fiscal 2025
$62.9M
As reported in the annual filing
Shares outstanding
31.1M
As of Oct 31, 2026
In fiscal 2025 the company spent $25.1M buying back its own shares. Cash actually paid, from its cash-flow statement.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
4 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Insider selling
Traded May 18 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade −26.5% · S&P 500 −6.6% · to Nov 20
A Collegium Pharmaceutical director sold $681 of Collegium Pharmaceutical shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$216M
+3.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$336M
This quarter $86.3M, a year earlier $78.3M
Net debt
—
Debt —, cash $145M, at Sep 30, 2026
Net income, last 12 months
$38.2M
Operating profit covers interest 1.62x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue and earnings history, 13 fiscal yearsEarnings dates and the stock's moves
Against the S&P 500 over the year
Since Nov 19, 2025, COLL is down 44.4% and the index fund is up 4.1%: 49 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much COLL moves
Beta 0.2 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Insiders of Collegium Pharmaceutical, Inc. reported 11 open-market purchases and 187 sales since 2015; purchases in 3 different years, most recently 2017.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $3.36M8×8 trades |
| 2025 | — | $12.4M30×30 trades |
| 2024 | — | $8.37M14×14 trades |
| 2023 | — | $8.48M19×19 trades |
| 2022 | — | $12.6M27×27 trades |
| 2021 | — | $4.38M15×15 trades |
| 2020 | — | $9.57M18×18 trades |
| 2019 | — | $5.08M19×19 trades |
| 2018 | — | $10M28×28 trades |
| 2017 | $92K1×1 trade | $35.5M9×9 trades |
| 2016 | $25K1×1 trade | — |
| 2015 | $13.2M9×9 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 24, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Collegium Pharmaceutical, Inc.'s own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Collegium Pharmaceutical, Inc.'s policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Millennium Management LLC
13G · passive · Amended · 2.4M shares · filed Oct 8, 2026
STATE STREET CORPORATION
13G · passive · Crossed 5% · 1.77M shares · filed Nov 10, 2026
Recent moves
FULLER & THALER ASSET MANAGEMENT, INC. fell below 5% (1.84%) · Schedule 13G, 2026
JANUS HENDERSON GROUP Ltd. fell below 5% (0.2%) · Schedule 13G, 2026
Invesco Ltd. fell below 5% (3.9%) · Schedule 13G, 2026
STATE STREET CORPORATION went above 5%, with 5.4% · Schedule 13G, 2026
Vanguard Capital Management fell below 5% (4.97%) · Schedule 13G, 2026
PRINCIPAL GLOBAL INVESTORS fell below 5% (4.7%) · Schedule 13G, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
0 certified in FY2026 Q3, vs 0 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 5, 2026. Quarterly reports are not audited. Read the filing
−0.9% on the same quarter a year earlier ($58.3M)
+24% on the same quarter a year earlier ($41.8M)
−9.2% on the same quarter a year earlier ($50.5M)
$0 the same quarter a year earlier
−48% on the same quarter a year earlier ($32M)
−57% on the same quarter a year earlier ($22.8M)
$0 the same quarter a year earlier
−10.0% on the same quarter a year earlier ($4.03M)
$0 the same quarter a year earlier
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 26, 2026. Read the filing
+4.9% on the year before ($211M)
+4.2% on the year before ($191M)
+300% on the year before ($37.2M)
+14% on the year before ($101M)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (“ADHD”) and moderate to severe pain. We commercialize our products, consisting of Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR (collectively the “Nucynta Products”), and Symproic, in the United States. Jornay PM is a central nervous system (“CNS”) stimulant prescription medicine that contains methylphenidate HCl, a Schedule II methylphenidate, which was approved by the U.S.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026 and Form 10-Q filed Nov 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Who holds it
Deals
Things to keep in mind
Records
+6.9% on the year before ($75.8M)
−4.3% on the year before ($15.1M)
And 17 more headings in the filing.
Latest annual report filed Feb 26, 2026, compared with the one filed Feb 27, 2025. Read the filing
Discussion of legal matters is incorporated by reference from Note 13, Commitments and Contingencies, to the Consolidated Financial Statements included in Item 8 of Part II of this Annual Report on Form 10-K.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 37.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (25.4% on ATS, 11.9% with other brokers), below its 26-week average of 40.5%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (14.4%), UBS ATS (12.2%), MS TRAJECTORY CROSS (ATS-1) (11.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.